P. Vermersch

561 total citations
28 papers, 247 citations indexed

About

P. Vermersch is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, P. Vermersch has authored 28 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 8 papers in Neurology and 6 papers in Rheumatology. Recurrent topics in P. Vermersch's work include Multiple Sclerosis Research Studies (9 papers), Peripheral Neuropathies and Disorders (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). P. Vermersch is often cited by papers focused on Multiple Sclerosis Research Studies (9 papers), Peripheral Neuropathies and Disorders (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). P. Vermersch collaborates with scholars based in France, Germany and Denmark. P. Vermersch's co-authors include J. de Sèze, T. Stojkovic, D. Ferriby, A. Destée, É. Hachulla, Pierre‐Yves Hatron, B. Wallaert, Djamel Bensmaïl, Tanya Stojkovic and C. A. Maurage and has published in prestigious journals such as Neurology, Journal of the Neurological Sciences and Multiple Sclerosis Journal.

In The Last Decade

P. Vermersch

26 papers receiving 238 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Vermersch France	8	85	78	66	65	57	28	247
Matthew Pugh United Kingdom	13	37 0.4×	70 0.9×	49 0.7×	68 1.0×	24 0.4×	29	328
D. Reske Germany	8	69 0.8×	117 1.5×	58 0.9×	41 0.6×	63 1.1×	18	264
Hui‐Ching Hsu Taiwan	11	54 0.6×	30 0.4×	27 0.4×	57 0.9×	52 0.9×	30	250
Daniele Doro Italy	11	43 0.5×	77 1.0×	17 0.3×	39 0.6×	48 0.8×	28	462
John Rubin United States	10	57 0.7×	22 0.3×	49 0.7×	71 1.1×	19 0.3×	25	259
Kim Uhas United States	4	40 0.5×	14 0.2×	53 0.8×	110 1.7×	106 1.9×	4	259
Toshihiro Kawai Japan	7	68 0.8×	60 0.8×	37 0.6×	37 0.6×	13 0.2×	19	360
Giuseppe Nascimbeni Italy	8	117 1.4×	24 0.3×	24 0.4×	35 0.5×	21 0.4×	9	350
Mark Sissons United Kingdom	11	30 0.4×	69 0.9×	158 2.4×	70 1.1×	20 0.4×	20	373
Hidemasa Kishimoto Japan	11	37 0.4×	82 1.1×	87 1.3×	61 0.9×	40 0.7×	33	380

Countries citing papers authored by P. Vermersch

Since Specialization

Citations

This map shows the geographic impact of P. Vermersch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Vermersch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Vermersch more than expected).

Fields of papers citing papers by P. Vermersch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Vermersch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Vermersch. The network helps show where P. Vermersch may publish in the future.

Co-authorship network of co-authors of P. Vermersch

This figure shows the co-authorship network connecting the top 25 collaborators of P. Vermersch. A scholar is included among the top collaborators of P. Vermersch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Vermersch. P. Vermersch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pelletier, Daniel, Douglas L. Arnold, Ann Bass, et al.. (2020). Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up. Multiple Sclerosis Journal. 26. 43–44. 2 indexed citations

Sprenger, Till, Christine Lebrun‐Frénay, P. Vermersch, et al.. (2019). Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study. European Journal of Neurology. 26. 864–864. 1 indexed citations

Vermersch, P., Juha-Pekka Erälinna, Rebecca Nicholas, et al.. (2019). Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1‑year interim results). Journal of the Neurological Sciences. 405. 310–310.

Rammohan, Kottil, Sandra Cook, Per Soelberg Sørensen, et al.. (2018). Cladribine Tablets 35 mg/kg Is Efficacious in Patients Aged Above and Below 45 Years with Relapsing Multiple Sclerosis in the Clarity Study. Multiple Sclerosis and Related Disorders. 26. 262–262. 2 indexed citations

Oreja‐Guevara, Celia, Raed Alroughani, David Brassat, et al.. (2017). Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study). Queensland's institutional digital repository (The University of Queensland). 1 indexed citations

Coles, Alasdair, Alexey Boyко, J. A. Cohen, et al.. (2016). Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. Multiple Sclerosis Journal. 22. 75–76. 7 indexed citations

Bensmaïl, Djamel & P. Vermersch. (2012). Épidémiologie et évaluation clinique de la spasticité dans la sclérose en plaques. Revue Neurologique. 168. S45–S50. 15 indexed citations

Outteryck, Olivier, J. de Sèze, T. Stojkovic, et al.. (2012). Methionine Synthase Deficiency (cblG): A Rare Cause of Adult Onset Leukoencephalopathy with Reversible Neurological Deficit (P01.124). Neurology. 78(Meeting Abstracts 1). P01.124–P01.124.

Paulin, Michael G., et al.. (2005). Man-in-the-barrel syndrome caused by a pontine lesion. Neurology. 64(10). 1703–1703. 9 indexed citations

10.

Sèze, J. de, et al.. (2003). Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurologica Scandinavica. 107(2). 154–157. 23 indexed citations

11.

Zéphir, Hélène, J. de Sèze, D. Ferriby, T. Stojkovic, & P. Vermersch. (2002). [Epstein-Barr meningoencephaloradiculitis in a immunocompetent woman].. PubMed. 158(8-9). 830–2. 3 indexed citations

12.

Sèze, J. de, T. Stojkovic, Christine Delmaire, et al.. (2002). [Candida albicans meningoencephalomyeloradiculitis].. PubMed. 158(4). 473–6. 1 indexed citations

13.

Ferriby, D., Tanya Stojkovic, J. de Sèze, Jean‐François Hurtevent, & P. Vermersch. (2002). [Chronic polyradiculoneuritis disclosing sarcoidosis].. PubMed. 158(3). 357–60. 2 indexed citations

14.

Zéphir, Hélène, J. de Sèze, Olivier Sénéchal, et al.. (2002). [Treatment of progressive multiple sclerosis with cyclophosphamide].. PubMed. 158(1). 65–9. 7 indexed citations

15.

Ferriby, D., J. de Sèze, T. Stojkovic, et al.. (2001). Long-term follow-up of neurosarcoidosis. Neurology. 57(5). 927–929. 83 indexed citations

16.

Sèze, J. de, et al.. (2001). [Sensory disorders in multiple sclerosis (before optic neuropathy)].. PubMed. 157(12). 1579–82. 2 indexed citations

17.

Mackowiak‐Cordoliani, Marie‐Anne, J. de Sèze, Tanya Stojkovic, et al.. (2001). [Sarcoidosis and progressive multifocal leukoencephalopathy].. PubMed. 157(5). 547–50. 7 indexed citations

18.

Krystkowiak, Pierre, et al.. (1998). [Collet-Sicard syndrome disclosing periarteritis nodosa].. PubMed. 154(11). 777–9. 9 indexed citations

19.

Krystkowiak, Pierre, P. Vermersch, G. Beaucaire, & H. Petit. (1997). [Regressive leukoencephalopathy in chronic brucellosis].. PubMed. 153(12). 781–4. 3 indexed citations

20.

Petit, H, P. Vermersch, & Florence Pasquier. (1992). Some clinical aspects of late onset parkinsonism. Clinical Neurology and Neurosurgery. 94. 137–138. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact